title: Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
abstract: Myelodysplastic syndrome (MDS) in children is often considered as a variant of acute myeloid leukemia (AML) and frequently treated as such. However, there are very few reported data on the outcome following AML treatment. We analyzed 20 consecutive cases of de novo MDS treated in Denmark according to the NOPHO AML protocols. The results were compared with those obtained in 31 children with de novo AML treated with the same protocols, and with the outcome in 10 children with MDS who received allogeneic bone marrow transplantation (BMT) without prior AML therapy. Distinction between MDS and AML was made morphologically according to the FAB criteria. All children were followed for at least 37 months. The proportion of complete remission in MDS and AML was 35 percent vs 74 percent. (P = 0.005), resistant disease 25 percent vs 10 percent (P = 0.14), death in cytopenia 40 percent vs 16 percent (P= 0.06), and 3-year survival 15 percent vs 35 percent. (P = 0.11), respectively. Duration of treatment-related cytopenia was similar in MDS and AML, except for a longer period of leukopenia in MDS following the second course of induction. Seven of 10 MDS children receiving BMT without prior chemotherapy are long-term survivors. Our data suggest that conventional AML regimens are associated with a low rate of complete remission, a high risk of death in cytopenia, and a limited curative potential in childhood MDS. Allogeneic BMT was in contrast associated with a high survival rate. BMT may, at least in some patients, be performed successfully without prior induction chemotherapy. The different response to therapy in MDS and AML may reflect fundamental biological differences between the two conditions.
authors.affiliation: Department of Pediatrics, Odense University Hospital, Denmark.
authors.forename: H
authors.initials: H
authors.lastname: Hasle
authors.forename: G
authors.initials: G
authors.lastname: Kerndrup
authors.forename: M
authors.initials: M
authors.lastname: Yssing
authors.forename: N
authors.initials: N
authors.lastname: Clausen
authors.forename: E
authors.initials: E
authors.lastname: Ostergaard
authors.forename: N
authors.initials: N
authors.lastname: Jacobsen
authors.forename: B B
authors.initials: BB
authors.lastname: Jacobsen
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D007958:Leukocyte Count; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000628:therapy*; D010976:Platelet Count; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D005047:Etoposide; D004317:Doxorubicin; D013866:Thioguanine